Explore first-line EGFR-mutated NSCLC options, when to intensify beyond osimertinib, and how brain/liver mets, ctDNA, TP53, and comorbidities guide choices.
Back
Prognostic Factors, FLAME and TOP Data, and the Role of ctDNA in Advanced NSCLC with Common EGFR Mutations
Two thoracic medical oncologists review how poor prognostic factors shape frontline treatment selection in EGFR-mutated advanced non-small cell lung cancer (NSCLC) and place data from the TOP study, FLAURA2 study, and FLAME trialinto practice context.
Prognostic Factors, FLAME and TOP Data, and the Role of ctDNA in Advanced NSCLC with Common EGFR Mutations
Episodes
All
All
The discussion turns to TP53 co-mutation as a molecular risk factor and to the TOP study.
The faculty examine circulating tumor DNA (ctDNA) as a tool for treatment selection.
The faculty discuss how these data are applied in practice and where real-world experience sits in the evidence hierarchy.
In closing, the faculty offer their top takeaways from the discussion and look ahead at how they anticipate the treatment landscape for EGFR-mutated advanced NSCLC evolving.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
2
Revisit Every OncLive On Air Episode From September 2026
3
Oral Azacitidine and Cedazuridine Meets Primary Pharmacokinetic End Point in MDS and CMML
4
Optune Pax Is Approved in Japan for Unresectable Locally Advanced Pancreatic Cancer
5